Skip to main content

Table 2 Pluripotent stem cell clinical trials (USA)

From: Clinical trials for stem cell therapies

Trial sponsor Disease target Cell therapy
Geron Inc.
Phase I: 10 patients
enrolled 2010-12
Complete subacute thoracic spinal cord injuries. T3 to T10 segments between seven and 14 days after injury Human embryonic stem cell derived Oligodendrocyte progenitor cells (GRNOPC1)
Advanced Cell Technologies (ACT)
Phase I/II: 12 patients Enrolled 2011
Stargardt's Macular Dystrophy (juvenile macular degeneration) Retinal Pigment Epithelium derived from human embryonic stem cells
Advanced Cell Technologies (ACT)
Phase I/II: 12 patients Enrolled 2011-12
Age-related Macular Degeneration Retinal Pigment Epithelium derived from human embryonic stem cells
California Stem Cell (CSC)
Phase I
Currently on hold 2011
Spinal muscular atrophy (SMA) Type 1 Human motor neuron progenitor cells derived from human embryonic stem cells